GT Medical Technologies
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, GT Medical Technologies sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
GT Medical Technologies: 4 sponsored US clinical trials, 2 recruiting.
GT Medical Technologies sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glioblastoma, with 2 trials.
Upper-quartile sponsor footprint
GT Medical Technologies sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
NCT07195591
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
NCT04427384
GammaTile and Stupp in Newly Diagnosed GBM
NCT05342883
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
NCT04365374
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
| Phase 4 | 1 |
Where GT Medical Technologies enrollment is open (later-stage tilt)
2 recruiting of 4 indexed (50% open).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Glioblastoma (2 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GT Medical Technologies: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
GT Medical Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this GT Medical Technologies page
4 registered trials is a research-attention snapshot, not an endorsement of GT Medical Technologies or any single study.
- 2 of GT Medical Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Glioblastoma is the condition GT Medical Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glioblastoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
GT Medical Technologies pipeline card: 4 registered trials from official public datasets.Report a data error.